Shibao L. Feng

No. 58 Renmin Avenue
Haikou, 570228, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.

Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.

Journal: Hepatology (Baltimore, Md.)
Published: November 14, 2025

Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis.

Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: August 05, 2025

Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy.

Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy.

Journal: Hepatology (Baltimore, Md.)
Published: March 10, 2025

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Journal: Nature medicine
Published: March 04, 2024

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.

Journal: Gut
Published: October 27, 2023

Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.

Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.

Journal: Alimentary pharmacology & therapeutics
Published: July 13, 2023

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Journal: The New England journal of medicine
Published: June 25, 2023

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Journal: Nature medicine
Published: January 29, 2023

Whale Optimization Algorithm for Multiconstraint Second-Order Stochastic Dominance Portfolio Optimization.

Whale Optimization Algorithm for Multiconstraint Second-Order Stochastic Dominance Portfolio Optimization.

Journal: Computational intelligence and neuroscience
Published: May 30, 2020

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Journal: Haematologica
Published: May 29, 2020

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.

Journal: Journal of hematology & oncology
Published: March 05, 2020

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal
Published: June 21, 2018
Showing 1-12 of 18

Last Updated: 09/26/2026